Top

Published in:

01-03-2019 | Short Communication

Fulminant diabetes induced by PD-1 and PD-L1 inhibitors: what about glucose variability?

Authors: Lucien Marchand, Sophie Reffet, Stéphane Dalle, Emmanuel Disse, Julien Vouillarmet, Christine Cugnet-Anceau, Charles Thivolet

Published in: Acta Diabetologica | Issue 3/2019

Excerpt

We read with interest the paper by Tassone et al., describing difficulties in achieving a good metabolic control and high glucose variability in a subject who presented nivolumab-induced fulminant diabetes (FD) [1]. These issues were not detailed in recent reviews and the large case series of diabetes induced by immune checkpoint inhibitors. …

Tassone F, Colantonio I, Gamarra E et al (2018) Nivolumab-induced fulminant type 1 diabetes (T1D): the first Italian case report with long follow-up and flash glucose monitoring. Acta diabetologica. https://doi.org/10.1007/s00592-018-1246-4 (PubMed PMID: 30361845) CrossRefPubMed

Monnier L, Colette C, Wojtusciszyn A et al (2017) Toward defining the threshold between low and high glucose variability in diabetes. Diabetes Care 40(7):832–838 (PubMed PMID: 28039172) CrossRefPubMed

Marchand L, Reffet S, Vouillarmet J, Cugnet-Anceau C, Disse E, Thivolet C (2018) The 36% coefficient of variation for glucose proposed for separating stable and labile diabetes is clinically relevant: a continuous glucose monitoring-based study in a large population of type 1 diabetes patients. Diabetes Metab. https://doi.org/10.1016/j.diabet.2018.05.009 (PubMed PMID: 29910090) CrossRefPubMed

Marchand L, Thivolet A, Dalle S et al (2018) Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype. Acta Diabetol. https://doi.org/10.1007/s00592-018-1234-8 (PubMed PMID: 30284618) CrossRefPubMed

Marchand L, Paulus V, Fabien N et al (2017) Nivolumab-induced acute diabetes mellitus and hypophysitis in a patient with advanced pulmonary pleomorphic carcinoma with a prolonged tumor response. J Thorac Oncol. 12(11):e182–e184 (PubMed PMID: 29074210) CrossRefPubMed

Title: Fulminant diabetes induced by PD-1 and PD-L1 inhibitors: what about glucose variability?
Authors: Lucien Marchand
Sophie Reffet
Stéphane Dalle
Emmanuel Disse
Julien Vouillarmet
Christine Cugnet-Anceau
Charles Thivolet
Publication date: 01-03-2019
Publisher: Springer Milan
Published in: Acta Diabetologica / Issue 3/2019
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI: https://doi.org/10.1007/s00592-018-1262-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Fulminant diabetes induced by PD-1 and PD-L1 inhibitors: what about glucose variability?

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2019

Comparison of correlations of equation-derived body fat percentage and body mass index with carotid intima-media thickness

Serum bilirubin concentrations, type 2 diabetes and incident coronary heart disease

Reply to comment: Serum bilirubin concentrations, type 2 diabetes, and incident coronary heart disease

The impact of a successful treatment of hepatitis C virus on glyco-metabolic control in diabetic patients: a systematic review and meta-analysis

Soluble ST2 is a biomarker for cardiovascular mortality related to abnormal glucose metabolism in high-risk subjects

Evaluation of health utility values for diabetic complications, treatment regimens, glycemic control and other subjective symptoms in diabetic patients using the EQ-5D-5L

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page